Article info
PDFCommentary
Risk stratification: an important tool in the special review of research using oocytes and embryos
- Correspondence to G Owen Schaefer, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; medgos{at}nus.edu.sg
Citation
Risk stratification: an important tool in the special review of research using oocytes and embryos
Publication history
- Received July 8, 2022
- Accepted July 12, 2022
- First published July 21, 2022.
Online issue publication
August 22, 2022
Article Versions
- Previous version (21 July 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Two kinds of embryo research: four case examples
- Research Ethics, Science Policy, and Four Contexts for the Stem Cell Debate
- A brief and personal history of ‘what’s in a name’ in reproductive genetics
- Creating and sacrificing embryos for stem cells
- How reproductive and regenerative medicine meet in a Chinese fertility clinic. Interviews with women about the donation of embryos to stem cell research
- What’s in a name? Embryos, entities, and ANTities in the stem cell debate
- Social egg freezing and donation: waste not, want not
- The need for donor consent in mitochondrial replacement
- Reproductive and therapeutic cloning, germline therapy, and purchase of gametes and embryos: comments on Canadian legislation governing reproduction technologies
- Research ethics and lessons from Hwanggate: what can we learn from the Korean cloning fraud?